KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Net Cash Flow (2016 - 2025)

Inovio Pharmaceuticals' Net Cash Flow history spans 16 years, with the latest figure at $12.2 million for Q3 2025.

  • For Q3 2025, Net Cash Flow rose 196.15% year-over-year to $12.2 million; the TTM value through Sep 2025 reached $14.9 million, up 422.1%, while the annual FY2024 figure was $51.5 million, 260.77% up from the prior year.
  • Net Cash Flow for Q3 2025 was $12.2 million at Inovio Pharmaceuticals, up from -$15.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $44.1 million in Q4 2024 and bottomed at -$167.1 million in Q1 2021.
  • The 5-year median for Net Cash Flow is -$12.1 million (2022), against an average of -$11.3 million.
  • The largest annual shift saw Net Cash Flow soared 1081.83% in 2024 before it crashed 592.49% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $3.2 million in 2021, then skyrocketed by 657.96% to $24.3 million in 2022, then tumbled by 118.47% to -$4.5 million in 2023, then skyrocketed by 1081.83% to $44.1 million in 2024, then tumbled by 72.32% to $12.2 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Net Cash Flow are $12.2 million (Q3 2025), -$15.6 million (Q2 2025), and -$25.9 million (Q1 2025).